张品良_好大夫在线
微信扫码

微信扫码关注医生

有问题随时问

收藏收藏

指南阅读

NSCLC靶向治疗NCCN指南:色瑞替尼Zykadia

发表者:张品良 人已读

Non-Small Cell Lung Cancer非小细胞肺癌

NCCN Guidelines Version 4.2016  NCCN指南2016第4版

Discussion 讨论

Treatment Approaches 治疗手段

Targeted Therapies 靶向治疗

Ceritinib 色瑞替尼(Zykadia, 诺华制药)

Ceritinib was recently approved by the FDA for patients with ALK-positive metastatic NSCLC who have progressed on or are intolerant to crizotinib. The approval is based on a recent expanded phase 1 study showing overall response rates of 56% to ceritinib in patients who had previously received crizotinib. Some patients with CNS lesions responded to ceritinib. Based on the study and the FDA approval, the NCCN Panel recommends ceritinib as subsequent therapy for patients with ALK-positive NSCLC who have progressed after crizotinib; patients who do not tolerant crizotinib may be switched to ceritinib or alectinib. 最近FDA批准色瑞替尼用于克唑替尼进展或不能耐受、ALK阳性的转移性NSCLC患者。批准是基于最近扩大1期研究显示在既往已接受克唑替尼的患者中色瑞替尼的总有效率56%。不耐受克唑替尼的患者可以转换至色瑞替尼或阿雷替尼。山东第一医科大学附属肿瘤医院呼吸内科张品良

本文为转载文章,如有侵权请联系作者删除。
本文仅供健康科普使用,不能做为诊断、治疗的依据,请谨慎参阅

收藏
×
分享到微信
打开微信“扫一扫”,即可分享该文章

发表于:2016-09-18 10:07

张品良大夫的信息

  • 感谢信: 0 感谢信 礼物: 0 礼物